

# Ronen Arbel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5295522/publications.pdf>

Version: 2024-02-01

19  
papers

647  
citations

1163117  
8  
h-index

794594  
19  
g-index

23  
all docs

23  
docs citations

23  
times ranked

808  
citing authors

#	ARTICLE	IF	CITATIONS
1	BNT162b2 Vaccine Booster and Mortality Due to Covid-19. New England Journal of Medicine, 2021, 385, 2413-2420.	27.0	288
2	Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nature Medicine, 2022, 28, 1486-1490.	30.7	100
3	Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. New England Journal of Medicine, 2022, 386, 1221-1229.	27.0	98
4	Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. American Journal of Medicine, 2019, 132, 847-855.e3.	1.5	67
5	PCSK9 inhibitors may improve cardiovascular outcomes—Can we afford them?. International Journal of Cardiology, 2016, 220, 242-245.	1.7	13
6	Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2019, 123, 1273-1276.	1.6	12
7	Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis. American Journal of Medicine, 2021, 134, e415-e419.	1.5	9
8	Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis. European Journal of Preventive Cardiology, 2021, 28, 1665-1669.	1.8	9
9	How many lives do COVID vaccines save? Evidence from Israel. American Journal of Infection Control, 2022, 50, 258-261.	2.3	8
10	Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality. American Journal of Cardiology, 2018, 122, 981-984.	1.6	7
11	Rethinking cost-effectiveness in the era of zero healthcare spending growth. International Journal for Equity in Health, 2016, 15, 33.	3.5	6
12	Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2021, 150, 65-68.	1.6	5
13	Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis. Clinical Drug Investigation, 2020, 40, 665-669.	2.2	5
14	Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus. American Journal of Cardiovascular Drugs, 2022, 22, 325-331.	2.2	4
15	Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillation. Heart, 2019, 105, 1487-1492.	2.9	3
16	Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2022, 170, 128-131.	1.6	2
17	Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 495-501.	1.4	1
18	Abstract 10153: Validation of the Cost Needed to Treat Measure. Circulation, 2021, 144, .	1.6	1

#	ARTICLE	IF	CITATIONS
19	Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6. Postgraduate Medicine, 0, , 1-5.	2.0	0